小细胞肺癌化疗联合免疫治疗:化疗骨架是否最优?
广泛期小细胞肺癌(ES-SCLC)预后极差,近三十年生存未见改善。近期三项大型临床研究显示在现有化疗方案基础上联合抗PD-(L)1抗体可带来生存获益,但获益幅度似乎不及非小细胞肺癌的化疗免疫联合治疗。本文假设当前ES-SCLC化疗骨架缺乏触发免疫原性细胞死亡的最佳药物,因而无法诱导化疗与免疫检查点抑制剂之间的协同作用,并主张重新考虑以多柔比星替代依托泊苷作为SCLC一线标准治疗。
要点
- ES-SCLC化疗联合抗PD-(L)1抗体有生存获益但幅度有限
- 作者假设现有化疗骨架不能充分触发免疫原性细胞死亡
- 主张重新评估多柔比星替代依托泊苷作为一线标准治疗
核心结论
- 当前ES-SCLC化疗骨架可能不含触发免疫原性细胞死亡的最佳药物,无法与免疫检查点抑制剂产生协同。
- 作者主张重新考虑以多柔比星替代依托泊苷作为SCLC一线标准治疗。
研究设计与样本
- 本文为简短报告(假设性论述),基于对近期三项大型临床研究的分析提出假设。
主要发现
- 近期三项大型临床研究显示在现有化疗方案基础上联合抗PD-(L)1抗体可带来生存获益。
- 该生存获益似乎不及非小细胞肺癌化疗免疫联合治疗的获益幅度。
临床怎么用
- 提示临床应重新审视ES-SCLC一线化疗骨架的选择,关注多柔比星替代依托泊苷的可行性。
局限性
- 本文为假设性论述,未提供新的临床研究数据验证多柔比星替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive cancer that remains very hard to treat. The life expectancy of a patient diagnosed with this disease has not changed over the past three decades. Recently, three large clinical studies showed a survival benefit by adding an anti-programmed death (ligand) 1 (PD-(L)1 antibody to the current chemotherapy regimen. Although significant and important, the benefit seems less than what has been achieved in patients with non-small-cell lung cancer treated with chemoimmunotherapy. A number of hypotheses have been explored to explain this discrepancy. Here, we hypothesise that the current chemotherapy backbone in ES-SCLC does not contain the optimal drugs to trigger immunogenic cell death and therefore does not induce a synergy between chemotherapy and immune checkpoint inhibitor therapy. Thereby, we advocate that doxorubicin treatment instead of etoposide should be reconsidered as standard-of-care (SoC) first-line treatment of SCLC.
引用
- Mankor JM, Zwierenga F, Dumoulin DW, et al. A brief report on combination chemotherapy and anti-programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone? Eur J Cancer. 2020. PMID: 32739768. doi:10.1016/j.ejca.2020.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。